| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:55 UTC |
|---|
| HMDB ID | HMDB0015267 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Carvedilol |
|---|
| Description | Carvedilol is only found in individuals that have used or taken this drug. It is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF).Carvedilol is a racemic mixture in which nonselective beta-adrenoreceptor blocking activity is present in the S(-) enantiomer and alpha-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol's beta-adrenergic receptor blocking ability decreases the heart rate, myocardial contractility, and myocardial oxygen demand. Carvedilol also decreases systemic vascular resistance via its alpha adrenergic receptor blocking properties. Carvedilol and its metabolite BM-910228 (a less potent beta blocker, but more potent antioxidant) have been shown to restore the inotropic responsiveness to Ca2+ in OH- free radical-treated myocardium. Carvedilol and its metabolites also prevent OH- radical-induced decrease in sarcoplasmic reticulum Ca2+-ATPase activity. Therefore, carvedilol and its metabolites may be beneficial in chronic heart failure by preventing free radical damage. |
|---|
| Structure | COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2 InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| (+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol | ChEBI | | Carvedilolum | ChEBI | | SKF 105517 | ChEBI | | Artist | Kegg | | Coreg | Kegg | | Dilatrend | HMDB | | Kredex | HMDB | | Carvedilol, (R)-isomer | HMDB | | Carvedilol, 14C-labeled | HMDB | | Coropres | HMDB | | Eucardic | HMDB | | Carvedilol hydrochloride | HMDB | | Carvedilol, (+-)-isomer | HMDB | | Querto | HMDB | | Carvedilol, (S)-isomer | HMDB | | Carvedilol, (-) | HMDB | | Carvedilol, 14C labeled | HMDB | | Carvedilol, (-)-isomer | HMDB | | 14C-Labeled carvedilol | HMDB | | Carvedilol, (+) | HMDB | | Carvedilol, (+)-isomer | HMDB |
|
|---|
| Chemical Formula | C24H26N2O4 |
|---|
| Average Molecular Weight | 406.4742 |
|---|
| Monoisotopic Molecular Weight | 406.18925733 |
|---|
| IUPAC Name | 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol |
|---|
| Traditional Name | 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol |
|---|
| CAS Registry Number | 72956-09-3 |
|---|
| SMILES | COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2 |
|---|
| InChI Identifier | InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3 |
|---|
| InChI Key | OGHNVEJMJSYVRP-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as carbazoles. Carbazoles are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Indoles and derivatives |
|---|
| Sub Class | Carbazoles |
|---|
| Direct Parent | Carbazoles |
|---|
| Alternative Parents | |
|---|
| Substituents | - Carbazole
- Indole
- Phenoxy compound
- Anisole
- Phenol ether
- Methoxybenzene
- Alkyl aryl ether
- Monocyclic benzene moiety
- Benzenoid
- Pyrrole
- Heteroaromatic compound
- Secondary alcohol
- 1,2-aminoalcohol
- Secondary amine
- Azacycle
- Secondary aliphatic amine
- Ether
- Organooxygen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organonitrogen compound
- Organic oxygen compound
- Amine
- Organic nitrogen compound
- Alcohol
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 114 - 115 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0044 g/L | Not Available | | LogP | 3.8 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.54 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 13.3487 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.46 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 45.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2104.9 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 280.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 202.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 206.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 223.3 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 548.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 466.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 116.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 984.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 566.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1427.4 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 404.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 365.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 340.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 186.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 7.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Carvedilol,1TMS,isomer #1 | COC1=CC=CC=C1OCCNCC(COC1=CC=CC2=C1C1=CC=CC=C1[NH]2)O[Si](C)(C)C | 3724.9 | Semi standard non polar | 33892256 | | Carvedilol,1TMS,isomer #2 | COC1=CC=CC=C1OCCN(CC(O)COC1=CC=CC2=C1C1=CC=CC=C1[NH]2)[Si](C)(C)C | 3763.0 | Semi standard non polar | 33892256 | | Carvedilol,1TMS,isomer #3 | COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C | 3749.0 | Semi standard non polar | 33892256 | | Carvedilol,2TMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1[NH]2)O[Si](C)(C)C)[Si](C)(C)C | 3781.2 | Semi standard non polar | 33892256 | | Carvedilol,2TMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1[NH]2)O[Si](C)(C)C)[Si](C)(C)C | 3546.1 | Standard non polar | 33892256 | | Carvedilol,2TMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1[NH]2)O[Si](C)(C)C)[Si](C)(C)C | 4541.5 | Standard polar | 33892256 | | Carvedilol,2TMS,isomer #2 | COC1=CC=CC=C1OCCNCC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C)O[Si](C)(C)C | 3669.4 | Semi standard non polar | 33892256 | | Carvedilol,2TMS,isomer #2 | COC1=CC=CC=C1OCCNCC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C)O[Si](C)(C)C | 3397.3 | Standard non polar | 33892256 | | Carvedilol,2TMS,isomer #2 | COC1=CC=CC=C1OCCNCC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C)O[Si](C)(C)C | 4300.7 | Standard polar | 33892256 | | Carvedilol,2TMS,isomer #3 | COC1=CC=CC=C1OCCN(CC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C)[Si](C)(C)C | 3715.0 | Semi standard non polar | 33892256 | | Carvedilol,2TMS,isomer #3 | COC1=CC=CC=C1OCCN(CC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C)[Si](C)(C)C | 3472.2 | Standard non polar | 33892256 | | Carvedilol,2TMS,isomer #3 | COC1=CC=CC=C1OCCN(CC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C)[Si](C)(C)C | 4495.5 | Standard polar | 33892256 | | Carvedilol,3TMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C)O[Si](C)(C)C)[Si](C)(C)C | 3742.9 | Semi standard non polar | 33892256 | | Carvedilol,3TMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C)O[Si](C)(C)C)[Si](C)(C)C | 3443.8 | Standard non polar | 33892256 | | Carvedilol,3TMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C)O[Si](C)(C)C)[Si](C)(C)C | 4170.4 | Standard polar | 33892256 | | Carvedilol,1TBDMS,isomer #1 | COC1=CC=CC=C1OCCNCC(COC1=CC=CC2=C1C1=CC=CC=C1[NH]2)O[Si](C)(C)C(C)(C)C | 3937.6 | Semi standard non polar | 33892256 | | Carvedilol,1TBDMS,isomer #2 | COC1=CC=CC=C1OCCN(CC(O)COC1=CC=CC2=C1C1=CC=CC=C1[NH]2)[Si](C)(C)C(C)(C)C | 4015.0 | Semi standard non polar | 33892256 | | Carvedilol,1TBDMS,isomer #3 | COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C(C)(C)C | 3888.2 | Semi standard non polar | 33892256 | | Carvedilol,2TBDMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1[NH]2)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4219.5 | Semi standard non polar | 33892256 | | Carvedilol,2TBDMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1[NH]2)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3904.1 | Standard non polar | 33892256 | | Carvedilol,2TBDMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1[NH]2)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4569.6 | Standard polar | 33892256 | | Carvedilol,2TBDMS,isomer #2 | COC1=CC=CC=C1OCCNCC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4001.0 | Semi standard non polar | 33892256 | | Carvedilol,2TBDMS,isomer #2 | COC1=CC=CC=C1OCCNCC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3776.6 | Standard non polar | 33892256 | | Carvedilol,2TBDMS,isomer #2 | COC1=CC=CC=C1OCCNCC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4339.3 | Standard polar | 33892256 | | Carvedilol,2TBDMS,isomer #3 | COC1=CC=CC=C1OCCN(CC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4086.7 | Semi standard non polar | 33892256 | | Carvedilol,2TBDMS,isomer #3 | COC1=CC=CC=C1OCCN(CC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3808.7 | Standard non polar | 33892256 | | Carvedilol,2TBDMS,isomer #3 | COC1=CC=CC=C1OCCN(CC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4501.1 | Standard polar | 33892256 | | Carvedilol,3TBDMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4280.5 | Semi standard non polar | 33892256 | | Carvedilol,3TBDMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3952.6 | Standard non polar | 33892256 | | Carvedilol,3TBDMS,isomer #1 | COC1=CC=CC=C1OCCN(CC(COC1=CC=CC2=C1C1=CC=CC=C1N2[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4245.4 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Carvedilol GC-MS (Non-derivatized) - 70eV, Positive | splash10-001j-2930000000-265c376e802c07cf1f2d | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Carvedilol GC-MS (1 TMS) - 70eV, Positive | splash10-001i-5911100000-80d7548a1e9097537fe6 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Carvedilol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Carvedilol , positive-QTOF | splash10-0a4i-1662900000-f901a62f255da92e9a09 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carvedilol , positive-QTOF | splash10-0a4i-0220900000-5821022307fc5077033b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carvedilol 35V, Negative-QTOF | splash10-0a59-0700900000-db48a63e0af377a4fd9a | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Carvedilol 35V, Positive-QTOF | splash10-05gi-0590400000-262b3137ced7d5771dd1 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 10V, Positive-QTOF | splash10-0a4i-0641900000-b122718c07e709b6e644 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 20V, Positive-QTOF | splash10-001i-2970100000-e3a225c7d81ac86276be | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 40V, Positive-QTOF | splash10-0pvi-5900000000-8e6d7ab1b80d6492009d | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 10V, Negative-QTOF | splash10-0a59-0920700000-a59fa070af5b3d3fc223 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 20V, Negative-QTOF | splash10-001i-0900000000-3815ea3eac5b157a1da0 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 40V, Negative-QTOF | splash10-001i-1900000000-1853ce1e2c70f7955fbe | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 10V, Positive-QTOF | splash10-0a59-0371900000-e534eced6a6fe12ecec4 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 20V, Positive-QTOF | splash10-0kcr-0981300000-ba8dc2f3b7ba5097647c | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 40V, Positive-QTOF | splash10-0udi-2910000000-f102425e265c4b7f8845 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 10V, Negative-QTOF | splash10-0a4i-0400900000-d652673d45eb1d8b982c | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 20V, Negative-QTOF | splash10-053r-2941300000-60c60407d2e97777ae0b | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Carvedilol 40V, Negative-QTOF | splash10-001i-0900000000-dcfc85c30b0adee491ca | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Vanderhoff BT, Ruppel HM, Amsterdam PB: Carvedilol: the new role of beta blockers in congestive heart failure. Am Fam Physician. 1998 Nov 1;58(7):1627-34, 1641-2. [PubMed:9824960 ]
- Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651-8. [PubMed:11386263 ]
- Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 Oct 22;106(17):2194-9. [PubMed:12390947 ]
|
|---|